Spotlight on Allergy & Immunology

Credits: 0.75 CME / CNE / CPE
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic
Jonathan A. Colasanti, MD, MSPH
Global Education Group

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Allergy & Immunology Presentations

1.00 CME
SHM (Society of Hospital Medicine)
Hospitalists Guide to COVID-19

Hospitalists Guide to COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

0.75 CME / CNE / CPE
Global Education Group
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

0.75 CME / CNE / CPE
Global Education Group
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 2: Overcoming Barriers: Successful Rapid ART Initiation

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 2: Overcoming Barriers: Successful Rapid ART Initiation

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 2, we will address common real-world barriers to rapid-ART implementation at the levels of systems, clinics, providers, and patients. We will then review guideline-based antiretroviral selection in the Rapid ART context and show how you can move beyond perceived barriers to quickly and safely initiate ART and achieve viral suppression.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-051-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 2, we will address common real-world barriers to rapid-ART implementation at the levels of systems, clinics, providers, and patients. We will then review guideline-based antiretroviral selection in the Rapid ART context and show how you can move beyond perceived barriers to quickly and safely initiate ART and achieve viral suppression.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-051-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

1.00 CME / CC
Vindico
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Investigating the Role of New and Emerging Biologic Therapies

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Investigating the Role of New and Emerging Biologic Therapies

Start

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABOHNS Continuing Certification
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, immunologists, otolaryngologists, and other health care professionals involved in the management of patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the underlying pathophysiology and differentiation of chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Review the rationale for the use of biologic therapies, including appropriate use in patients with CRSwNP who have had an inadequate response to conventional treatments.
  • Evaluate the clinical trial data of new and emerging biologic therapies based on their mechanisms of action, safety, and efficacy for the treatment of patients with CRSwNP.

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a challenge for otolaryngologists, allergists, and immunologists alike. This disease recurs in up to 80% of patients after sinus surgery followed by medical treatment, and about 40% of patients may need at least one further surgery over the next 10 years. The pathogenesis of CRSwNP is elusive, and differentiating subtypes is challenging. Emerging biologic therapies hold promise in treating this debilitating condition. In this interactive educational activity, the pathogenesis and treatment of CRSwNP is discussed by expert clinicians.

Agenda

Underlying Immunopathology of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Whitney W. Stevens, MD, PhD, FAAAAI

Overview of Treatment of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Michael S. Blaiss, MD

A Look at the Clinical Evidence of New and Emerging Biologics
Joseph K. Han MD, FARS, FAAAAI

Activity Chair

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Augusta, GA

Disclosure:
Consulting Fee: ALK, Covis, Merck, Pfizer, Sanofi/Regeneron

Faculty

Joseph K. Han MD, FARS, FAAAAI
Professor – Eastern Virginia Medical School
Norfolk, VA

Disclosure:
Consulting Fee: AstraZeneca, Genentech, GlaxoSmithKline, Intersect, Medtronic, OptiNose, Sanofi Genzyme

Whitney W. Stevens, MD, PhD, FAAAAI
Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure:
Consulting Fee: Bristol Myers Squibb, Genentech, GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABOHNS Continuing Certification
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, immunologists, otolaryngologists, and other health care professionals involved in the management of patients with chronic rhinosinusitis with nasal polyps.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the underlying pathophysiology and differentiation of chronic rhinosinusitis with nasal polyps (CRSwNP).
  • Review the rationale for the use of biologic therapies, including appropriate use in patients with CRSwNP who have had an inadequate response to conventional treatments.
  • Evaluate the clinical trial data of new and emerging biologic therapies based on their mechanisms of action, safety, and efficacy for the treatment of patients with CRSwNP.

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a challenge for otolaryngologists, allergists, and immunologists alike. This disease recurs in up to 80% of patients after sinus surgery followed by medical treatment, and about 40% of patients may need at least one further surgery over the next 10 years. The pathogenesis of CRSwNP is elusive, and differentiating subtypes is challenging. Emerging biologic therapies hold promise in treating this debilitating condition. In this interactive educational activity, the pathogenesis and treatment of CRSwNP is discussed by expert clinicians.

Agenda

Underlying Immunopathology of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Whitney W. Stevens, MD, PhD, FAAAAI

Overview of Treatment of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Michael S. Blaiss, MD

A Look at the Clinical Evidence of New and Emerging Biologics
Joseph K. Han MD, FARS, FAAAAI

Activity Chair

Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Augusta, GA

Disclosure:
Consulting Fee: ALK, Covis, Merck, Pfizer, Sanofi/Regeneron

Faculty

Joseph K. Han MD, FARS, FAAAAI
Professor – Eastern Virginia Medical School
Norfolk, VA

Disclosure:
Consulting Fee: AstraZeneca, Genentech, GlaxoSmithKline, Intersect, Medtronic, OptiNose, Sanofi Genzyme

Whitney W. Stevens, MD, PhD, FAAAAI
Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure:
Consulting Fee: Bristol Myers Squibb, Genentech, GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Getting the Diagnosis Right Early: Clinical Pearls for Identifying EOE in Children and Adults

Getting the Diagnosis Right Early: Clinical Pearls for Identifying EOE in Children and Adults

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: April 30, 2021
Expires: April 29, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This curriculum is designed for gastroenterologists, allergists and immunologists, pediatric gastroenterologists, pediatric allergists and immunologists, and NPs/PAs who diagnose and manage patients with eosinophilic esophagitis.

Learning Objective

Upon completion of the educational activity, participants should be able to:

  • Use evidence-based diagnostic approaches to detect eosinophilic esophagitis (EoE) early in children and adults

Activity Description

This 15-minute infographic-based educational activity will be augmented by patient and clinician videos, in addition to an interactive approach to cover diagnostic approaches to detect EoE early.

Statement of Educational Need

The significant burden of disease and increasing incidence and prevalence of eosinophilic esophagitis (EoE) in the United States require that several knowledge and practice gaps among clinicians involved in the care of affected patients be addressed; diagnostic delays continue to present a challenge to the timely management of EoE.

Agenda

  1. Incidence, prevalence, and underlying pathophysiology of EoE
  2. Symptomatology and natural history of EoE
  3. Diagnostic strategies for patients with a high index of suspicion for EoE
  4. Challenges associated with diagnosis and consequences of diagnostic delay

Chair

Evan S. Dellon, MD, MPH
Professor of Medicine, Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure Declaration

FACULTY DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consultant); Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda (Contracted Research - paid to institution); Allakos, Banner, Holoclara (Other: Educational grants - paid to institution)

STAFF AND REVIEWERS DISCLOSURES
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.  AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

During the period April 30, 2021 through April 29, 2022, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the evaluation form

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: April 30, 2021
Expires: April 29, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This curriculum is designed for gastroenterologists, allergists and immunologists, pediatric gastroenterologists, pediatric allergists and immunologists, and NPs/PAs who diagnose and manage patients with eosinophilic esophagitis.

Learning Objective

Upon completion of the educational activity, participants should be able to:

  • Use evidence-based diagnostic approaches to detect eosinophilic esophagitis (EoE) early in children and adults

Activity Description

This 15-minute infographic-based educational activity will be augmented by patient and clinician videos, in addition to an interactive approach to cover diagnostic approaches to detect EoE early.

Statement of Educational Need

The significant burden of disease and increasing incidence and prevalence of eosinophilic esophagitis (EoE) in the United States require that several knowledge and practice gaps among clinicians involved in the care of affected patients be addressed; diagnostic delays continue to present a challenge to the timely management of EoE.

Agenda

  1. Incidence, prevalence, and underlying pathophysiology of EoE
  2. Symptomatology and natural history of EoE
  3. Diagnostic strategies for patients with a high index of suspicion for EoE
  4. Challenges associated with diagnosis and consequences of diagnostic delay

Chair

Evan S. Dellon, MD, MPH
Professor of Medicine, Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure Declaration

FACULTY DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consultant); Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda (Contracted Research - paid to institution); Allakos, Banner, Holoclara (Other: Educational grants - paid to institution)

STAFF AND REVIEWERS DISCLOSURES
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.  AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

During the period April 30, 2021 through April 29, 2022, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the evaluation form

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

0.50 CME / CPE
Vindico
DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 58-Year-Old Woman With HIV and History of Medication Intolerance

DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 58-Year-Old Woman With HIV and History of Medication Intolerance

Start

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 58-year-old woman with HIV, multiple comorbidities, and history of medication intolerance.

Faculty

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Honoraria: Mediahuset

Planning Committee

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-007-H02-P, effective 4/30/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 58-year-old woman with HIV, multiple comorbidities, and history of medication intolerance.

Faculty

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Honoraria: Mediahuset

Planning Committee

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-007-H02-P, effective 4/30/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME / CPE
Vindico
HIV Management: Clinical Case Conundrums – A Wheel of Knowledge Challenge

HIV Management: Clinical Case Conundrums – A Wheel of Knowledge Challenge

Start

Activity Details

Free CME/CPE
0.50 AMA PRA Category 1 Credit(s)
0.50 ACPE Contact Hour(s)
Released: April 23, 2021
Expires: April 22, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate new evidence-based guidelines for the use of antiretroviral (ARV) agents in adults and adolescents with HIV.
  • Initiate treatment in ARV-naive patients, based on individual patient needs, characteristics, preferences, and genotypic drug-resistance testing.
  • Interpret recent evidence regarding the use of antiretroviral therapy (ART) in women of childbearing potential.
  • Incorporate the use of switching ART regimens in patients who have experienced adverse events.
  • Implement the most appropriate regimens in patients with HIV and comorbidities.
  • Recognize the complexities of HIV management in older, highly treatment-experienced patients due to polypharmacy, drug-drug interactions, and other issues.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on the latest clinical developments and management strategies for patients with HIV as an expert faculty member provides guidance on how to incorporate new treatment strategies into clinical practice. Your host will also discuss various aspects of HIV management, including selection of a patient’s initial antiretroviral regimen, treatment modification in highly treatment-experienced patients, and individualizing therapy.

Faculty

Host:
W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Keck School of Medicine of USC
Los Angeles, CA

Disclosure:
Consulting Fee: Enochian BioSciences, Gilead, Merck, ViiV/GlaxoSmithKline

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Contracted Research (Paid to Institution):
ViiV

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.50 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-008-H02-P, effective 4/23/2021. This is a knowledge-based activity, and there is no fee to attend.

MIPS Qualifying Activity
Vindico has identified this CE activity as an improvement activity in the Merit-based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement MIPS of QPP, accredited CE providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP ID and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE
0.50 AMA PRA Category 1 Credit(s)
0.50 ACPE Contact Hour(s)
Released: April 23, 2021
Expires: April 22, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate new evidence-based guidelines for the use of antiretroviral (ARV) agents in adults and adolescents with HIV.
  • Initiate treatment in ARV-naive patients, based on individual patient needs, characteristics, preferences, and genotypic drug-resistance testing.
  • Interpret recent evidence regarding the use of antiretroviral therapy (ART) in women of childbearing potential.
  • Incorporate the use of switching ART regimens in patients who have experienced adverse events.
  • Implement the most appropriate regimens in patients with HIV and comorbidities.
  • Recognize the complexities of HIV management in older, highly treatment-experienced patients due to polypharmacy, drug-drug interactions, and other issues.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on the latest clinical developments and management strategies for patients with HIV as an expert faculty member provides guidance on how to incorporate new treatment strategies into clinical practice. Your host will also discuss various aspects of HIV management, including selection of a patient’s initial antiretroviral regimen, treatment modification in highly treatment-experienced patients, and individualizing therapy.

Faculty

Host:
W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Keck School of Medicine of USC
Los Angeles, CA

Disclosure:
Consulting Fee: Enochian BioSciences, Gilead, Merck, ViiV/GlaxoSmithKline

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Contracted Research (Paid to Institution):
ViiV

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.50 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-008-H02-P, effective 4/23/2021. This is a knowledge-based activity, and there is no fee to attend.

MIPS Qualifying Activity
Vindico has identified this CE activity as an improvement activity in the Merit-based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement MIPS of QPP, accredited CE providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP ID and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at CME@VindicoCME.com

0.50 CME / CPE
Vindico
DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 52-Year-Old Man With HIV and Multiple Comorbidities Presents With Chronic Diarrhea

DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 52-Year-Old Man With HIV and Multiple Comorbidities Presents With Chronic Diarrhea

Start

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 21, 2021
Expires: April 20, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 52-year-old man with HIV and multiple comorbidities who presents with chronic diarrhea.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Planning Committee

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-006-H02-P, effective 4/21/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 21, 2021
Expires: April 20, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 52-year-old man with HIV and multiple comorbidities who presents with chronic diarrhea.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Planning Committee

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-006-H02-P, effective 4/21/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 ABIM / CME / MOC
Forefront Collaborative
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

0.50 CME
Vindico
Gaining Control in Moderate to Severe Asthma: A GameOn! Challenge

Gaining Control in Moderate to Severe Asthma: A GameOn! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 23, 2021
Expires: March 22, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for the activity is allergists, immunologists, pulmonologists, and other health care professionals involved in the management of patients with asthma.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the latest advances in treatment that target specific asthma phenotypes.
  • Outline the features of uncontrolled or persistent asthma and strategies for treatment intensification.
  • Examine the latest evidence regarding new options for uncontrolled asthma and how these agents may fit into existing treatment algorithms.

Activity Description

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Guidelines from the European Respiratory Society as well as the American Thoracic Society recommend phenotypic assessment and consideration of select add-on biologic therapy for severe, poorly controlled asthma. Biologic therapies that modulate immunoglobulin E, interleukin (IL)-4/13, and IL-5 signaling pathways offer important options for patients whose asthma is inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing moderate to severe asthma will better enable health care professionals to tailor an individualized, targeted treatment approach. This Game On! activity is an interactive quiz in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. Through this gaming activity, faculty will highlight advances in treatment that target specific asthma phenotypes; outline features of poorly controlled asthma and strategies for treatment intensification; and review the latest evidence regarding options for uncontrolled asthma.

Activity Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, Sentien, Teva
Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi
Contracted Research: AstraZeneca, Sanofi

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 23, 2021
Expires: March 22, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for the activity is allergists, immunologists, pulmonologists, and other health care professionals involved in the management of patients with asthma.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the latest advances in treatment that target specific asthma phenotypes.
  • Outline the features of uncontrolled or persistent asthma and strategies for treatment intensification.
  • Examine the latest evidence regarding new options for uncontrolled asthma and how these agents may fit into existing treatment algorithms.

Activity Description

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Guidelines from the European Respiratory Society as well as the American Thoracic Society recommend phenotypic assessment and consideration of select add-on biologic therapy for severe, poorly controlled asthma. Biologic therapies that modulate immunoglobulin E, interleukin (IL)-4/13, and IL-5 signaling pathways offer important options for patients whose asthma is inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing moderate to severe asthma will better enable health care professionals to tailor an individualized, targeted treatment approach. This Game On! activity is an interactive quiz in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. Through this gaming activity, faculty will highlight advances in treatment that target specific asthma phenotypes; outline features of poorly controlled asthma and strategies for treatment intensification; and review the latest evidence regarding options for uncontrolled asthma.

Activity Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, Sentien, Teva
Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi
Contracted Research: AstraZeneca, Sanofi

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages